- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating HS Management: The Patient Journey
A panelist discusses how guidelines are important for knowing when patient care starts, the progress of the patients care, and if the patient is satisfied with the response. Treatment guidelines are available for the 3 stages of hidradenitis suppurativa (HS): Hurley 1, Hurley 2, and Hurley 3. High scar scoring is also used to examine improvement in scarring over time. In real-world cases, guidelines have little to no impact on physicians treating HS, and most people often go to urgent care centers or primary care physicians when they are experiencing symptoms of HS. Health providers do not utilize guidelines except in clinical trials.
EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa
EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity
EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care
EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa
EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa
EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes
EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models
EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes
EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management
EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence
EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions
EP: 12.Navigating HS Management: The Patient Journey
EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement
EP: 14.Tailoring HS Treatment: The Path to Better Patient Outcomes
Video content above is prompted by the following:
- In your view, why are guidelines for managing HS important to improving patient care and outcomes?
- What treatment guidelines are available to support the management of HS?
- How do current guidelines address the challenges of underdiagnosis or misdiagnosis of HS?
- Is it common for patients to seek care that is more costly or ineffective?
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups
May 16th 2025This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.
Read More
